Literature DB >> 33948855

Differentially expressed miR-20, miR-21, miR-100, miR-125a and miR-146a as a potential biomarker for prostate cancer.

Mohan Damodaran1, Mohanapriya Chinambedu Dandapani2, S VenkatRamanan3, Ilangovan Ramachandran4, Vettriselvi Venkatesan5.   

Abstract

Prostate cancer is the leading cause of death among men worldwide. Deregulation of microRNAs has been reported in many cancers. Expression of microRNAs miR-20a-5p, miR-21-5p, miR-100-5p, miR-125a-5p and miR-146a-5p in tissue blocks of histologically confirmed prostate cancer patients compared with BPH patients, to identify potential microRNA biomarker for prostate cancer. MicroRNA was isolated and expression was quantified by qRT-PCR using Taqman Advanced microRNA assay kits. The interactions between the microRNA:target mRNA were predicted by using bioinformatics tools such as miRwalk and miRTargetlink. The experimentally validated targets were analysed using gprofiler to identify their molecular function, biological process and related pathways. The expression analysis revealed that miR-21 and miR-100 were significantly down-regulated whereas miR-125a was up-regulated in prostate cancer patients. Comparative analysis of the expression levels with tumor grading reveal that miR-100 was significantly down-regulated (p < 0.05) in high grade tumor, indicating that miR-100 associated with prostate cancer. ROC analysis revealed that combined analysis of down-regulated miRNAs (miR-21 and miR-100) shown AUC of 0.72 (95% CI 0.65-0.79). The combined analysis of all five miRNAs showed AUC of 0.87 (95% CI 0.81-0.92). The targets prediction analysis revealed several validated targets including BCL2, ROCK1, EGFR, PTEN, MTOR, NAIF1 and VEGFA. Our results provide evidence that combined analysis of all the five miRNAs as a panel can significantly improve the prediction level of the presence of prostate cancer and may be used as a potential diagnostic biomarker.

Entities:  

Keywords:  Benign Prostate Hyperplasia (BPH); Biomarker; FFPE (Formalin-Fixed Paraffin embedded); Microrna; Prostate cancer; ROC (Receiver Operating Curve); Target enrichment

Year:  2021        PMID: 33948855     DOI: 10.1007/s11033-021-06384-z

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  21 in total

Review 1.  Microdissecting the role of microRNAs in the pathogenesis of prostate cancer.

Authors:  Shiekh Gazalla Ayub; Deepak Kaul; Taha Ayub
Journal:  Cancer Genet       Date:  2015-03-02

Review 2.  Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy.

Authors:  Andrea L Kasinski; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2011-11-24       Impact factor: 60.716

3.  MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening.

Authors:  Sven Wach; Elke Nolte; Jaroslaw Szczyrba; Robert Stöhr; Arndt Hartmann; Torben Ørntoft; Lars Dyrskjøt; Elke Eltze; Wolf Wieland; Bastian Keck; Arif B Ekici; Friedrich Grässer; Bernd Wullich
Journal:  Int J Cancer       Date:  2011-05-09       Impact factor: 7.396

Review 4.  Biomarkers in prostate cancer surveillance and screening: past, present, and future.

Authors:  K Clint Cary; Mathew R Cooperberg
Journal:  Ther Adv Urol       Date:  2013-12

5.  A Review on the Clinical Utility of PSA in Cancer Prostate.

Authors:  Mohan Adhyam; Anish Kumar Gupta
Journal:  Indian J Surg Oncol       Date:  2012-03-03

6.  A miRNA expression signature that separates between normal and malignant prostate tissues.

Authors:  Jessica Carlsson; Sabina Davidsson; Gisela Helenius; Mats Karlsson; Zelmina Lubovac; Ove Andrén; Björn Olsson; Karin Klinga-Levan
Journal:  Cancer Cell Int       Date:  2011-05-27       Impact factor: 5.722

Review 7.  Epidemiology of prostate cancer in India.

Authors:  Shalu Jain; Sunita Saxena; Anup Kumar
Journal:  Meta Gene       Date:  2014-08-29

8.  Downregulation of miR-199a-5p promotes prostate adeno-carcinoma progression through loss of its inhibition of HIF-1α.

Authors:  Jinjing Zhong; Rui Huang; Zhengzheng Su; Mengni Zhang; Miao Xu; Jing Gong; Ni Chen; Hao Zeng; Xueqin Chen; Qiao Zhou
Journal:  Oncotarget       Date:  2017-05-31

Review 9.  Epidemiology of Prostate Cancer.

Authors:  Prashanth Rawla
Journal:  World J Oncol       Date:  2019-04-20

Review 10.  MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications.

Authors:  Carlos Stahlhut; Frank J Slack
Journal:  Genome Med       Date:  2013-12-30       Impact factor: 11.117

View more
  3 in total

1.  The Overexpression of TOB1 Induces Autophagy in Gastric Cancer Cells by Secreting Exosomes.

Authors:  Yanhong Wang; Ying Song; Lijie Zhou; Mengxi Wang; Dong Wang; Jing Bai; Songbin Fu; Jingcui Yu
Journal:  Dis Markers       Date:  2022-04-12       Impact factor: 3.464

Review 2.  Dietary stilbenes as modulators of specific miRNAs in prostate cancer.

Authors:  Anait S Levenson
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

3.  Expression Analysis of miRNAs and Their Potential Role as Biomarkers for Prostate Cancer Detection.

Authors:  Fernando Bergez-Hernández; Eliakym Arámbula-Meraz; Marco Alvarez-Arrazola; Martín Irigoyen-Arredondo; Fred Luque-Ortega; Alejandra Martínez-Camberos; Dora Cedano-Prieto; José Contreras-Gutiérrez; Carmen Martínez-Valenzuela; Noemí García-Magallanes
Journal:  Am J Mens Health       Date:  2022 Sep-Oct
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.